|
SLC25A1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.75960000015074E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.55610000055029E-07 |
| Normal-vs-Stage2 |
9.147800E-01 |
| Normal-vs-Stage3 |
4.51930000089362E-08 |
| Normal-vs-Stage4 |
2.040200E-04 |
| Stage1-vs-Stage2 |
6.695300E-03 |
| Stage1-vs-Stage3 |
4.839000E-01 |
| Stage1-vs-Stage4 |
6.549200E-01 |
| Stage2-vs-Stage3 |
3.518400E-03 |
| Stage2-vs-Stage4 |
2.461700E-02 |
| Stage3-vs-Stage4 |
3.568600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.41849999968358E-07 |
| Normal-vs-AfricanAmerican |
1.221790E-03 |
| Normal-vs-Asian |
9.36710000010166E-07 |
| Caucasian-vs-AfricanAmerican |
9.543200E-01 |
| Caucasian-vs-Asian |
3.280400E-01 |
| AfricanAmerican-vs-Asian |
5.287000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.10399999999567E-05 |
| Normal-vs-Female |
1.3178000002334E-07 |
| Male-vs-Female |
4.736800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.92119999698326E-08 |
| Normal-vs-Age(41-60Yrs) |
2.5545000004179E-07 |
| Normal-vs-Age(61-80Yrs) |
5.031700E-02 |
| Normal-vs-Age(81-100Yrs) |
1.830350E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.718800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.524040E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.735200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.518400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.616800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.049400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.817800E-04 |
| Classical-VS-Follicular |
2.482200E-03 |
| Classical-VS-Other |
7.262400E-01 |
| Classical-VS-Normal |
2.1514000025924E-08 |
| Tall-VS-Follicular |
1.08489999994799E-06 |
| Tall-VS-Other |
3.068800E-01 |
| Tall-VS-Normal |
1.59061652738046E-12 |
| Follicular-VS-Other |
4.731600E-01 |
| Follicular-VS-Normal |
1.976010E-01 |
| Other-VS-Normal |
2.081000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.420580E-04 |
| Normal-vs-N1 |
9.34599999613539E-08 |
| N0-vs-N1 |
1.395870E-02 |
|
|
